Selecta turns to synbio player for $1.1B capsid deal; BioNTech signs $790M immunotherapy deal
Selecta Biosciences has turned to one of the recent darlings in the synbio biz for its latest collaboration.
Ginkgo Bioworks has signed on to a biobucks-heavy deal to work on next-gen gene therapy viral capsids for Selecta, a hot topic in an industry that has identified a full slate of issues with the early-gen AAV vehicles that have dominated the first-gen programs. This is their second capsid-focused collaboration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
